IDEXX LABORATORIES INC (IDXX) Fundamental Analysis & Valuation

NASDAQ:IDXX • US45168D1046

Current stock price

553.66 USD
-14.64 (-2.58%)
At close:
553.66 USD
0 (0%)
After Hours:

This IDXX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. IDXX Profitability Analysis

1.1 Basic Checks

  • IDXX had positive earnings in the past year.
  • IDXX had a positive operating cash flow in the past year.
  • Each year in the past 5 years IDXX has been profitable.
  • IDXX had a positive operating cash flow in each of the past 5 years.
IDXX Yearly Net Income VS EBIT VS OCF VS FCFIDXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • With an excellent Return On Assets value of 31.62%, IDXX belongs to the best of the industry, outperforming 98.93% of the companies in the same industry.
  • With an excellent Return On Equity value of 65.99%, IDXX belongs to the best of the industry, outperforming 99.47% of the companies in the same industry.
  • IDXX's Return On Invested Capital of 41.85% is amongst the best of the industry. IDXX outperforms 100.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for IDXX is significantly above the industry average of 9.12%.
  • The 3 year average ROIC (37.64%) for IDXX is below the current ROIC(41.85%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 31.62%
ROE 65.99%
ROIC 41.85%
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.64%
ROIC(5y)38.05%
IDXX Yearly ROA, ROE, ROICIDXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • IDXX's Profit Margin of 24.62% is amongst the best of the industry. IDXX outperforms 95.19% of its industry peers.
  • IDXX's Profit Margin has improved in the last couple of years.
  • IDXX's Operating Margin of 31.60% is amongst the best of the industry. IDXX outperforms 98.93% of its industry peers.
  • In the last couple of years the Operating Margin of IDXX has grown nicely.
  • IDXX has a better Gross Margin (61.80%) than 62.03% of its industry peers.
  • IDXX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 31.6%
PM (TTM) 24.62%
GM 61.8%
OM growth 3Y5.77%
OM growth 5Y4.3%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
IDXX Yearly Profit, Operating, Gross MarginsIDXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. IDXX Health Analysis

2.1 Basic Checks

  • IDXX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, IDXX has less shares outstanding
  • Compared to 5 years ago, IDXX has less shares outstanding
  • Compared to 1 year ago, IDXX has an improved debt to assets ratio.
IDXX Yearly Shares OutstandingIDXX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IDXX Yearly Total Debt VS Total AssetsIDXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • IDXX has an Altman-Z score of 20.91. This indicates that IDXX is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 20.91, IDXX belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
  • The Debt to FCF ratio of IDXX is 0.81, which is an excellent value as it means it would take IDXX, only 0.81 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of IDXX (0.81) is better than 90.37% of its industry peers.
  • A Debt/Equity ratio of 0.48 indicates that IDXX is not too dependend on debt financing.
  • IDXX has a Debt to Equity ratio (0.48) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 0.81
Altman-Z 20.91
ROIC/WACC4.7
WACC8.9%
IDXX Yearly LT Debt VS Equity VS FCFIDXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 1.23 indicates that IDXX should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.23, IDXX is not doing good in the industry: 86.63% of the companies in the same industry are doing better.
  • IDXX has a Quick Ratio of 1.23. This is a bad value and indicates that IDXX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • IDXX has a worse Quick ratio (0.90) than 84.49% of its industry peers.
  • The current and quick ratio evaluation for IDXX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 0.9
IDXX Yearly Current Assets VS Current LiabilitesIDXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. IDXX Growth Analysis

3.1 Past

  • IDXX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.18%, which is quite good.
  • The Earnings Per Share has been growing by 14.26% on average over the past years. This is quite good.
  • The Revenue has grown by 10.42% in the past year. This is quite good.
  • The Revenue has been growing by 9.72% on average over the past years. This is quite good.
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%

3.2 Future

  • Based on estimates for the next years, IDXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.69% on average per year.
  • IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.94% yearly.
EPS Next Y13.3%
EPS Next 2Y13.11%
EPS Next 3Y13.25%
EPS Next 5Y12.69%
Revenue Next Year9.17%
Revenue Next 2Y8.88%
Revenue Next 3Y9%
Revenue Next 5Y8.94%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
IDXX Yearly Revenue VS EstimatesIDXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B
IDXX Yearly EPS VS EstimatesIDXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

4

4. IDXX Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 42.36, the valuation of IDXX can be described as expensive.
  • Based on the Price/Earnings ratio, IDXX is valued a bit cheaper than 67.38% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.54, IDXX is valued quite expensively.
  • The Price/Forward Earnings ratio is 37.39, which means the current valuation is very expensive for IDXX.
  • Based on the Price/Forward Earnings ratio, IDXX is valued a bit cheaper than 70.05% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 21.68, IDXX is valued quite expensively.
Industry RankSector Rank
PE 42.36
Fwd PE 37.39
IDXX Price Earnings VS Forward Price EarningsIDXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • 68.98% of the companies in the same industry are more expensive than IDXX, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than the industry average as 73.80% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 42.14
EV/EBITDA 30.16
IDXX Per share dataIDXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of IDXX may justify a higher PE ratio.
  • IDXX's earnings are expected to grow with 13.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.19
PEG (5Y)2.97
EPS Next 2Y13.11%
EPS Next 3Y13.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IDXX Dividend Analysis

5.1 Amount

  • No dividends for IDXX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IDXX Fundamentals: All Metrics, Ratios and Statistics

IDEXX LABORATORIES INC

NASDAQ:IDXX (4/29/2026, 6:16:43 PM)

After market: 553.66 0 (0%)

553.66

-14.64 (-2.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength9.94
Industry Growth61.49
Earnings (Last)02-02
Earnings (Next)05-05
Inst Owners95.6%
Inst Owner Change-0.01%
Ins Owners0.21%
Ins Owner Change1.92%
Market Cap43.97B
Revenue(TTM)4.30B
Net Income(TTM)1.06B
Analysts80.91
Price Target755.47 (36.45%)
Short Float %2.62%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.79%
Min EPS beat(2)3.12%
Max EPS beat(2)6.47%
EPS beat(4)4
Avg EPS beat(4)4.78%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.3%
EPS beat(12)12
Avg EPS beat(12)4.65%
EPS beat(16)14
Avg EPS beat(16)3.71%
Revenue beat(2)1
Avg Revenue beat(2)0.36%
Min Revenue beat(2)-0.31%
Max Revenue beat(2)1.03%
Revenue beat(4)2
Avg Revenue beat(4)0.17%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.74%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)3
Avg Revenue beat(16)-1.15%
PT rev (1m)-1.71%
PT rev (3m)-3.58%
EPS NQ rev (1m)-0.29%
EPS NQ rev (3m)-0.58%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)0.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.42%
Valuation
Industry RankSector Rank
PE 42.36
Fwd PE 37.39
P/S 10.22
P/FCF 42.14
P/OCF 37.21
P/B 27.39
P/tB 40.66
EV/EBITDA 30.16
EPS(TTM)13.07
EY2.36%
EPS(NY)14.81
Fwd EY2.67%
FCF(TTM)13.14
FCFY2.37%
OCF(TTM)14.88
OCFY2.69%
SpS54.19
BVpS20.21
TBVpS13.62
PEG (NY)3.19
PEG (5Y)2.97
Graham Number77.0998 (-86.07%)
Profitability
Industry RankSector Rank
ROA 31.62%
ROE 65.99%
ROCE 61.77%
ROIC 41.85%
ROICexc 44.96%
ROICexgc 57.39%
OM 31.6%
PM (TTM) 24.62%
GM 61.8%
FCFM 24.25%
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.64%
ROIC(5y)38.05%
ROICexc(3y)42.76%
ROICexc(5y)42.28%
ROICexgc(3y)54.98%
ROICexgc(5y)55.56%
ROCE(3y)53.48%
ROCE(5y)55.19%
ROICexgc growth 3Y6.58%
ROICexgc growth 5Y1.33%
ROICexc growth 3Y7.31%
ROICexc growth 5Y1.49%
OM growth 3Y5.77%
OM growth 5Y4.3%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
F-Score8
Asset Turnover1.28
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 0.81
Debt/EBITDA 0.51
Cap/Depr 95.21%
Cap/Sales 3.21%
Interest Coverage 36.08
Cash Conversion 78.51%
Profit Quality 98.5%
Current Ratio 1.23
Quick Ratio 0.9
Altman-Z 20.91
F-Score8
WACC8.9%
ROIC/WACC4.7
Cap/Depr(3y)104.09%
Cap/Depr(5y)113.7%
Cap/Sales(3y)3.41%
Cap/Sales(5y)3.73%
Profit Quality(3y)93.28%
Profit Quality(5y)84.36%
High Growth Momentum
Growth
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
EPS Next Y13.3%
EPS Next 2Y13.11%
EPS Next 3Y13.25%
EPS Next 5Y12.69%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
Revenue Next Year9.17%
Revenue Next 2Y8.88%
Revenue Next 3Y9%
Revenue Next 5Y8.94%
EBIT growth 1Y20.53%
EBIT growth 3Y14.78%
EBIT growth 5Y14.44%
EBIT Next Year22.79%
EBIT Next 3Y14.89%
EBIT Next 5Y13.4%
FCF growth 1Y30.76%
FCF growth 3Y39.53%
FCF growth 5Y14.08%
OCF growth 1Y27.21%
OCF growth 3Y29.59%
OCF growth 5Y12.77%

IDEXX LABORATORIES INC / IDXX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?

ChartMill assigns a fundamental rating of 7 / 10 to IDXX.


What is the valuation status for IDXX stock?

ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.


What is the profitability of IDXX stock?

IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.


What are the PE and PB ratios of IDEXX LABORATORIES INC (IDXX) stock?

The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 42.36 and the Price/Book (PB) ratio is 27.39.


Can you provide the financial health for IDXX stock?

The financial health rating of IDEXX LABORATORIES INC (IDXX) is 8 / 10.